TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06411821: Ulixertinib in People With Histiocytic Neoplasms

Sponsor: Memorial Sloan Kettering Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 38 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,755,600

Rescue Site Savings

+$1,155,000

Unlock Full NCT06411821 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06411821 Rescue Dossier →